Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Stock Information for Tevogen Bio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tevogen Bio Holdings Inc.

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.